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Combination of the anti-CD30-auristatin-E antibody-drug
conjugate (SGN-35) with chemotherapy improves antitumour
activity in Hodgkin lymphoma
CD30 is a member of the tumour necrosis factor receptor
superfamily and displays limited expression on normal tissues,
restricted to activated B and T lymphocytes. CD30 is also
expressed in malignancies, including Hodgkin lymphoma
(HL), anaplastic large-cell lymphoma (ALCL), immunoblastic
lymphoma, multiple myeloma, adult T-cell lymphoma leukae-
mia, germ-cell malignancies and thyroid carcinoma (reviewed
in Younes & Kadin, 2003). As CD30 is undetectable on
parenchymal cells in healthy tissues or resting monocytes and
lymphocytes, it represents an ideal target for immunotherapy
for the treatment of cancer.
We previously reported potent antitumour effects of the
cAC10-vcMMAE (SGN-35) drug conjugate in models of HL
and ALCL (Francisco et al, 2003). The antibody-drug conju-
gate (ADC) contains a peptide linker (valine–citrulline) that is
subject to cleavage by lysosomal enzymes following internal-
ization into target cells (Francisco et al, 2003). Release of
monomethyl auristatin E (MMAE) into the cytosol induces
G2/M-phase growth arrest and cell death through the induc-
tion of apoptosis of CD30-positive tumours (Francisco et al,
2003). Administration of SGN-35 to mice carrying ALCL and
HL tumours induces tumour regressions (Hamblett et al,
2004). The unconjugated cAC10 antibody SGN-30 (Wahl et al,
2002) and SGN-35 are both under evaluation in clinical trials
for the treatment of CD30-positive haematological malignan-
cies, including ALCL and HL (Schnell & Borchmann, 2006).
Recurrent and refractory HL remains an unmet medical
need and new strategies to further improve outcome and to
reduce therapy-induced complications are needed. The ABVD
chemotherapy regimen, consisting of repeated cycles of
doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD),
is considered a reasonable standard of care in the ﬁrst line
treatment of HL. ABVD, administered either alone or com-
bined with irradiation therapy, results in 2-year survival rates
of >90% [reviewed in (Klimm et al, 2005)]. Relapse rates after
ﬁrst line treatment range from 5% for early stage disease to
35% for patients with advanced disease. Patients with relapsed
and refractory HL typically receive platinum-based combina-
tion chemotherapy salvage regimens followed by high dose
chemotherapy and autologous stem cell transplantation (Byrne
& Gockerman, 2007). Long-term complications vary by
treatment regimen and modality. These complications include
infertility, cardiopulmonary toxicity and secondary malignan-
cies, including breast cancer and lymphomas. Gemcitabine is
an active and reasonably well-tolerated therapy for the salvage
treatment of HL. In relapsed or refractory transplant-naı ¨ve
patients receiving gemcitabine, a 39% response rate with an
overall survival time of 10Æ7 months in the absence of any
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Summary
The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin
inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-
CD30 monoclonal antibody cAC10. This ADC potently interferes with the
growth of CD30-positive haematological tumours, including Hodgkin
lymphoma (HL) and anaplastic large-cell lymphoma. This study found
improved antitumour activity in a preclinical model of HL when SGN-35 was
combined with chemotherapeutic regimens such as ABVD (doxorubicin,
bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efﬁcacy
was also observed in high tumour burden models, indicating that combining
ADCs with chemotherapeutic agents may be advantageous for the treatment
of patients with relapsed or refractory HL.
Keywords: SGN-35, antibody-drug conjugate, ABVD, gemcitabine, Hodgkin
lymphoma.
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novel treatment options with improved therapeutic indices are
needed for the treatment of HL, particularly for the treatment
of relapsed or refractory patients. This may be achieved by
targeting cytotoxic agents more speciﬁcally to tumour cells.
The present study demonstrated that combining an ADC
selectively targeting a tumour antigen on neoplastic cells with
conventional chemotherapy can signiﬁcantly improve anti-
tumour responses in HL without impacting toxicity.
Materials and methods
Compounds tested include adriamycin (0Æ75 mg/kg, q4dx3,
i.v.; Bedford Labs, Bedford, OH, USA), bleomycin (6 mg/kg,
q4dx3, i.p.; Sicor Pharmaceuticals, Irvine, CA, USA), vinblas-
tine (0Æ01 mg/kg, q4dx3, i.p.; Bedford Labs), dacarbazine
(Sicor Pharmaceuticals), gemcitabine (120 mg/kg, q4dx3, i.p.;
Eli Lilly and Company, Indianapolis, IN, USA) or vinorelbine
(4 mg/kg,q5dx3,i.p.;PierreFabrePharmaceuticals,Parsippany,
NJ, USA). The L540cy tumour model and SGN-35 were
described previously (Francisco et al, 2003). To determine the
maximum tolerated dose (MTD) of ABVD and gemcitabine,
body weights of severe combined immunodeﬁcient (SCID)
mice were assessed daily after treatment with increasing
amounts of drugs. The criteria deﬁning the MTD were ‡20%
decrease in body weights or other signs of morbidity during
the entire treatment followed by a 2-week recovery period.
Tumour quadrupling or tripling times were chosen as time-
to-endpoint (TTE), which were determined by using the
nonlinear regression analysis for exponential growth of each
individual tumour growth data set from each experimental
animal. The tumour quadrupling time was calculated based on
the tumour volume at the beginning of treatment. Animals
that did not reach this endpoint were assigned a TTE-value
equal to the last day of the study. %TGD (tumour growth
delay) reﬂects the delay in reaching TTE relative to control-
treated tumours, which was determined by using the formula:
%TGD = [(T)C)/C] · 100, where T and C are the median
times in days for treated and control groups, to reach TTE,
using the start of treatment as day 1. Statistical analysis and
graphic presentations were conducted using Prism (Graph-
Pad) software for Windows 3.03 software. Tumour growth
curves show group mean tumour volumes as a function of
time. Data shown are from one representative of two
independent experiments. The Logrank test was used to
analyse the signiﬁcance of the differences between TTE of
treated and control tumour groups, with differences deemed
signiﬁcant (*) at 0Æ01 £ P £ 0Æ05, and highly signiﬁcant (**) at
P £ 0Æ01.
Results and discussion
The ABVD regimen combines the different mechanisms of
action of four anticancer agents. Adriamycin and bleomycin
both interfere with DNA synthesis and repair, while vincristine
prevents the formation of microtubules and dacarbazine is an
alkylating agent that blocks cellular replication by forming
cross-linkages between DNA strands. The maximally tolerated
dose and schedule for each chemotherapeutic regimen was
determined in preceding tolerability studies in tumour-free
SCID mice as described in the Methods. The 1 mg/kg, q4dx3
treatment schedule for SGN-35 was selected based on previous
reports demonstrating maximal therapeutic effects at a q4dx4
schedule (Francisco et al, 2003). Administration of ABVD or
SGN-35 alone to L540cy tumour-bearing mice induced
tumour regressions and signiﬁcant TGD compared with
control treatment (Fig 1A), resulting in 0/8 and 4/9 durable
responses in ABVD and SGN-35-treated animals respectively.
In contrast, combination of SGN-35 with ABVD resulted in
9/9 durable tumour regressions in all experimental animals
(Fig 1A) and a statistically signiﬁcant increase in TGD relative
to each treatment arm alone (combination versus SGN-35:
P <0 Æ0101, combination versus ABVD: P <0 Æ0001). Similarly,
when treatment was initiated when tumours reached 300 mm
3
volume, the combination of SGN-35 with ABVD signiﬁcantly
increased the TGD, resulting in 50% durable responses (5/10
animals; Fig. 1B). The delay in tumour growth induced by the
combination treatment was highly signiﬁcant relative to each
individual treatment arm alone (combination versus SGN-35:
P <0 Æ05, combination versus ABVD: P <0 Æ001; Fig. 1C).
Next, we studied the effects of combining SGN-35 with
gemcitabine, a pyrimidine antimetabolite that inhibits DNA
synthesis and is increasingly used for the treatment of
relapsed and refractory HL patients because of its favourable
safety and activity proﬁle. For this purpose, mice were
implanted with L540cy tumours and treated with SGN-35
and gemcitabine, either alone or combined. While single
agent treatment led to signiﬁcant delays in tumour growth,
the combination of SGN-35 with gemcitabine enhanced
the antitumour activity and induced durable responses in
all animals (5/5, Fig 2A, combination versus SGN-35:
P <0 Æ0088, combination versus gemcitabine: P <0 Æ0014).
Improved activity in the combination treatment group was
also noted when drug administration occurred when tumours
reached a substantially larger size (300 mm
3; Fig 2B). Similar
to the ABVD experiment, combination treatment with
gemcitabine resulted in a signiﬁcant delay in tumour growth,
which was more than additive (combination versus SGN-35:
P <0 Æ0375, combination versus gemcitabine: P <0 Æ0154;
Fig 2C) and frequently led to durable responses. Importantly,
the combination of SGN-35 with other chemotherapeutic
agents, such as vinorelbine, did not uniformly improve
efﬁcacy, suggesting that the effects were chemotherapy-
speciﬁc (Fig S1). Finally, no signiﬁcant differences in body
weight loss or morbidity were noted in the ABVD and
gemcitabine combination groups (Fig S2), indicating compa-
rable tolerability in this experimental model. It is worth
noting that SGN-35 does not cross-react with rodent CD30
and therefore, the tolerability comparison is based on the off-
target toxicity of SGN-35. To determine the effects of
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detailed toxicological studies in reactive species such as
cynomolgus monkeys, will be required. To our knowledge,
this is the ﬁrst report demonstrating improved therapeutic
beneﬁt when combining ADCs targeting tumour-speciﬁc
antigens with chemotherapeutic agents in preclinical models.
Better understanding of the mechanism causing the
improvement in activity when combining SGN-35 with certain
chemotherapy regimens may help to further reﬁne the
treatment. One possible cause could be drug interference with
target expression. However, immunohistochemical staining of
tumours did not reveal signiﬁcant changes in CD30 expression
in sections from tumours treated with either ABVD or
gemcitabine, ruling-out this possibility (data not shown).
Alternatively, differences between the cell types targeted by
each class of compounds may account for improved activity.
SGN-35 is directed towards neoplastic Reed Sternberg cells,
which typically comprise only 0Æ1–1% of the total cell
population within HL lesions (Bai et al, 2005). Chemothera-
peutic agents, in addition to tumour cells, also target
proliferating stromal cell inﬁltrates, which constitute the
majority of the cell populations within HL lesions (Kuppers
& Rajewsky, 1998). Thus, a model based on the reduction of
neoplastic tumour cells by the ADC and a concomitant
interference with supporting stromal cells by the chemother-
apy may account for the increase in therapeutic activity.
Secondly, differences in the mechanism of action between
auristatin-based ADCs and chemotherapeutic compounds may
help to explain the increase in efﬁcacy. In support of this
hypothesis, SGN-35 induces G2/M-phase growth arrest (Fran-
cisco et al, 2003), whereas gemcitabine blocks the cell cycle in
S-phase (Zupi et al, 2005). ABVD is most commonly used for
the treatment of HL (Duggan et al, 2003) and the individual
compounds induce cell cycle arrest at all stages during cell
division (Chabner et al, 2001). Auristatins, vinorelbine and
vinblastine are cell cycle-speciﬁc agents, belonging to the vinca
alkaloids that have slightly different mechanisms of action,
partly as a result of the differences in their interaction with
microtubule-associated proteins. Therefore, the increase in
antitumour activity of SGN-35 in combination with gemcit-
abine and ABVD, but not vinorelbine, suggests that the efﬁcacy
improvements are speciﬁc for the type of cytotoxic compound
and their mechanism of action. In conclusion, our ﬁndings
provide a rationale for the design of clinical studies combining
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Fig 1. Antitumour activity of SGN-35 in combination with ABVD on subcutaneous L540cy Hodgin-lymphoma (HL) tumours in severe combined
immunodeﬁcient (SCID) mice. SCID mice were implanted with L540cy HL cells in the right ﬂank. Groups of mice (9–10/group) were untreated or
receivedSGN-35(1 mg/kg,q4dx3, i.p.) and/or ABVD [Adriamycin (0Æ75 mg/kg, q4dx3,i.v.), Bleomycin (6 u/kg,q4dx3, i.p.),Vinblastine(0Æ01 mg/kg,
q4dx3, i.p.) and Dacarbazine (15 mg/kg, q3dx4, i.p.)] when tumour size averaged approximately 100 mm
3 (A) or 300 mm
3 (B). The onset and
duration of treatment is indicated by the bars within the ﬁgures. Bars within the graph represent standard deviation. (C) Median delay to a four- or
threefold increase in tumour size (days) relative to untreated tumours are shown for individual treatment groups shown in panel A and B respectively.
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gemcitabine, with the goal to achieve improved efﬁcacy,
acceptable safety and reduced long-term complications in
patients with HL.
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Supplementary material
The following supplementary material is available for this
article online:
Fig S1. Antitumour activity of SGN-35 in combination with
vinorelbine in a subcutaneous of L540cy HL tumours in SCID
mice. SCID mice were implanted with L540cy HL cells in the
right ﬂank. Groups of mice (9–10/group) were either untreated
or received SGN-35 (1 mg/kg, q4dx3, i.p.) and/or Gemcitabine
(4 mg/kg, q5dx3, i.p.) when tumour size averaged approxi-
mately 100 mm
3.
Fig S2. Mean percent body weight change of L540cy HL
tumour bearing animals. (A) ABVD study. Groups of mice (9–
10/group) were either untreated or received SGN-35 (1 mg/kg,
q4dx3, i.p.) and/or ABVD [Adriamycin (0Æ75 mg/kg, q4dx3,
i.v.), Bleomycin (6 mg/kg, q4dx3, i.p.), Vinblastine (0Æ01
mg/kg, q4dx3, i.p.) and Dacarbazine (15 mg/kg, q3dx4, i.p.)].
(B) Gemcitabine study. Groups of mice (5–10/group) were
untreated or received SGN-35 (1 mg/kg, q4dx3, i.p.) and/or
gemcitabine (120 mg/kg, q4dx3, i.p.). Onset of the treatments
is labelled as day 0.
The material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.
2008.07146.x
(This link will take you to the article abstract).
Please note: Blackwell Publishing are not responsible for the
content or functionality of any supplementary materials sup-
plied by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
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